Search Page
Save citations to file
Email citations
On or after July 28, sending email will require My NCBI login.
Learn more about this and other changes coming to the email feature.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. doi: 10.1158/1078-0432.CCR-23-0974.
Clin Cancer Res. 2023.
PMID: 37265425
Free PMC article.
Clinical Trial.
Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study.
Brantly ML, Kuhn BT, Farah HW, Mahadeva R, Cole A, Chang CL, Brown CD, Campos MA, Lascano JE, Babcock EK, Bhagwat SP, Boyea TF, Veldstra CA, Andrianov V, Kalabus JL, Eckelman BP, Veale AG.
Brantly ML, et al. Among authors: veldstra ca.
Chronic Obstr Pulm Dis. 2024 May 29;11(3):282-292. doi: 10.15326/jcopdf.2023.0469.
Chronic Obstr Pulm Dis. 2024.
PMID: 38809792
Free PMC article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.